Clinical Risk Score is Superior to Fasting C‐peptide–Based β‐Cell Function Markers in Predicting Insulin Requirement in Individuals With Type 2 Diabetes

Key Points

• Clinical risk scores predict insulin requirements better than fasting beta-cell function markers, highlighting their utility.
• Individuals with non-insulin-deficient type 2 diabetes demonstrate a clearer need for clinical risk scores over fasting c-peptide levels.
• Observational analysis evaluated clinical characteristics against fasting c-peptide levels in predicting insulin needs.
• This approach highlights potential improvements in diabetes management, indicating the need for refined predictive tools.